Abbott India Share Price

healthcare solutions across multiple therapeutic areas, including women’s health, gastroenterology, central nervous system, metabolics, multi-specialty, vaccines, and consumer health. Some of its well-known global products include Brufen, Prothiaden, Thyronorm, and Leptos.

Business Divisions

Abbott India Ltd. operates through four key divisions, each catering to specific therapeutic areas and addressing diverse healthcare needs.

Primary Care Division: This division is mainly concerned with pain management and gastroenterology, providing a variety of medicines aimed at delivering relief from chronic and acute pain and solutions for digestive wellness. Being well established in these categories, Abbott India offers reliable brands that serve millions of patients suffering from conditions like acid reflux, irritable bowel syndrome (IBS), and gastrointestinal discomfort.

Specialty Care – Metabolics & Urology: This division deals with metabolic diseases and urology, providing specialized care for thyroid diseases, obesity, diabetes, and benign prostatic hyperplasia (BPH). Owing to the increasing trend of lifestyle diseases, Abbott India is constantly working on developing better solutions that enable the management of metabolic well-being and the quality of life of patients suffering from chronic conditions.

Specialty Care – Neuroscience: Committed to psychiatry and neurology, this division offers groundbreaking therapies for neuro and mental health disorders. Abbott India's neuroscience portfolio consists of drugs for conditions like epilepsy, Parkinson's disease, depression, and anxiety disorders. The company is committed to developing research in this area so that patients get effective and researched therapies.

Hospital Care: This business unit is very important in critical care and hospital treatments, providing products utilized in anesthesiology and neonatology. Among its main products are Forane and Sevorane, commonly utilized inhalation anesthetics, and Survanta, which is a life-saving drug for neonatal respiratory distress syndrome (RDS) of premature infants. Abbott India's Hospital Care business unit assists healthcare professionals with quality solutions to enhance patient outcomes in surgical and neonatal care.

Company History and Name Changes

Originally known as Boots Pure Drug Company (India) Ltd., Abbott India Ltd. was incorporated on August 22, 1944. The company has changed its name many times over the years as part of its corporate rebranding. It became The Boots Company (India) Ltd. in 1971 and rebranded again to Boots Pharmaceuticals Ltd. in 1991. Incorporating Knoll Pharmaceuticals Ltd. in 1995 marked the company’s expansion to a global healthcare market. Lastly, the firm aligned itself with its parent company, Abbott Laboratories, by rebranding to Abbott India Ltd. in 2002, and further strengthened its foothold in the Indian pharmaceutical sector.

Major Milestones and Expansions

To boost market presence and manufacturing capabilities in India, Abbott India has made several strategic acquisitions and expansion projects over the years. In 2002, the company undertook a restructuring strategy and divested its Jejuri Undertakings. The following year, Abbott India merged its other subsidiary, Lenbrook Pharmaceuticals Ltd. In the years 2004 to 2008, the firm increased production of its capsules, tablets, and nutritional products along with launching new medicines like Digene Total and Brugel.

In 2008, Abbott India conducted a buyback of 7.97 lakh equity shares at ₹630 per share, reflecting its commitment to enhancing shareholder value. A major development occurred between 2010 and 2011 when Solvay Pharma India Ltd. was merged into Abbott India, increasing its promoter shareholding to 74.98%. In 2013, its parent company, Abbott Laboratories, separated into two publicly traded firms, resulting in the formation of AbbVie Inc., which focused on research-based pharmaceuticals. In 2014, Abbott India shifted its financial year-end from December 31 to March 31, aligning its financial reporting structure with regulatory norms.

Product Launches and Market Strategies

Abbott India has consistently expanded its product portfolio, launching innovative solutions across various therapeutic segments, which benefits the Abbott India share price. In 2015, the company introduced Arachitol Nano in its General Care Division, marking a significant step in its vitamin D therapy offerings. The following year, in 2016, Abbott India launched 17 new products, which contributed 1.9% of its net sales.

The company continued its growth in 2017 by partnering with Bharat Biotech India Ltd. for vaccine marketing, strengthening its position in the immunization sector. In 2018, Abbott India established the GI Advance Business Unit, which led to the launch of key products in women’s health, gastroenterology, central nervous system (CNS), and consumer care.

In 2019, Abbott India was recognized as “The Most Innovative MNC of the Year” at the 12th Pharma Leaders Award, a testament to its commitment to research and development. The company further demonstrated its innovation in 2020 and 2021 with advancements in its Brufen Coating Formula, which resulted in a 50% increase in production capacity.

Recent Developments

Abbott India continues to expand its portfolio, with 10 new differentiated products launched in 2022, increasing its presence in adult vaccination and menopause treatments. The company has strengthened multichannel engagement using technology to interact with patients and healthcare professionals (HCPs). Strategic partnerships with key associations have helped shape therapy standards, and multimedia campaigns have been used to create awareness about vertigo, epilepsy, influenza, vitamin D, and insomnia.

Brief Overview

Abbott India Ltd. has established itself as a leading player in the pharmaceutical industry, driven by innovation, strategic expansions, and a strong commitment to improving healthcare. With a diversified product portfolio across primary care, specialty care, and hospital care, the company continues to address critical medical needs in India. Abbott India remains committed to improving patient outcomes and achieving further sustainable growth by continuing to invest in research and development and forming strategic relationships with other companies. Looking ahead, this is an opportunity for the company to use its knowledge, established global relations, and powerful brand for further growth and development in the Indian healthcare industry, which will be beneficial for the Abbott India share price.